Equity
€839,344 ▲ 10.9%
XTRAPHARMA paid out €60,000 in dividends. That is 42% of the 2025 profit.
XTRAPHARMA
Lifetime
5 annual accounts with figures on one time axispeak €459,743 (2022)
€228,023▲ 43.8%
peak €343,031 (2022)
€142,634▲ 70.7%
peak €839,344 (2025)
€839,344▲ 10.9%
€1.3m▼ 7.7%
Board2 names since 2020
1 directorNaoufal ESSRIFI
Documentsfilings and deeds
29-07-20262 days before the deadline
2025abbreviated format
Gross margin from €158,591 to €228,023Result from €83,557 to €142,634Dividend €60,000Cash from €83,879 to €266,028
Key points
from the 2025 annual accountsChecked score
87
Excellent
Financially stronger than 56% of small companies in wholesale trade (NACE 46)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.2% across 4,374 companies (NACE 46, small).
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 7.6%
01-2025: 10.2%▲ +2.6 percentage points vs 12-2024highest value
02-2025: 10.2%● unchanged vs 01-2025highest value
03-2025: 5.2%▼ -5.0 percentage points vs 02-2025
04-2025: 4.8%▼ -0.4 percentage points vs 03-2025
05-2025: 4.8%● unchanged vs 04-2025
06-2025: 4.7%▼ -0.1 percentage points vs 05-2025
07-2025: 4.7%● unchanged vs 06-2025
08-2025: 6.2%▲ +1.5 percentage points vs 07-2025
09-2025: 6.2%● unchanged vs 08-2025
10-2025: 6.2%● unchanged vs 09-2025
11-2025: 6.6%▲ +0.4 percentage points vs 10-2025
12-2025: 0.9%▼ -5.7 percentage points vs 11-2025
01-2026: 0.9%● unchanged vs 12-2025
02-2026: 0.9%● unchanged vs 01-2026
03-2026: 0.9%● unchanged vs 02-2026
04-2026: 0.9%● unchanged vs 03-2026
05-2026: 1.0%▲ +0.1 percentage points vs 04-2026
06-2026: 1.0%● unchanged vs 05-2026
07-2026: 1.1%▲ +0.1 percentage points vs 06-2026
08-2026: 0.3%▼ -0.8 percentage points vs 07-2026
09-2026: 0.3%● unchanged vs 08-2026
10-2026: 0.3%● unchanged vs 09-2026lowest value
11-2026: 0.3%● unchanged vs 10-2026lowest value
Financial strengthAverage
Score breakdown
raises risk
2 of the last 3 accounts late
Founded in 2020
lowers risk
Size: total assets €2.2m
Figures for financial year 2025 (filed on 29-07-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small). It does better than 45% of them on solvency, 34% on liquidity, 76% on profitability and 69% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 6,782 companies had the same profile as XTRAPHARMA has now. Each dot stands for 17 companies, two years later.
96.7%
were still trading
2.7%
stopped another way
0.6%
went bankrupt
That fits the bankruptcy probability of XTRAPHARMA itself: 0.3% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,782 companies, not a prediction for XTRAPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €70,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 1.55 (1.44 in 2024), above the usual 1.5. Short-term debt is 61.3% and cash 12.3% of total assets. However, 61.3% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
2 days early
2024
117 days late
2023
477 days late
2022
92 days late
2021
194 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 5 accounts on average 176 days after the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 25 November (4 of the last 5 accounts filed within 119 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0751561839
Registered office moved from Laeken to Haren
New registered office: Rue de la paroisse 22- 1130 HAREN · Previous registered office: Avenue de versaille 20, 1020 LAEKEN · Gazette deed
Registered office moved from Etterbeek to Laeken
New registered office: Avenue de versaille 20, 1020 LAEKEN · Previous registered office: Rue Abbé Cuypers 3, 1040 Etterbeek · Gazette deed
Transfer of 100 shares from Mounir EDDAIF to Naoufal ESSRIFI
Resignation: Mounir EDDAIF (director) · Appointment: Naoufal ESSRIFI (director) · Director discharge: Mounir EDDAIF · General meeting of 15-10-2020 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| XTRAPHARMA Brussels | €2.2m | €228,023 | 38.7% | - |
| MEDIM Kruisem | €1.9m | €349,936 | 40.5% | - |
| PROTEX HEALTHCARE Roeselare | €2.8m | €324,298 | 7.6% | 1 |
| LÖWENSTEIN MEDICAL BELGIUM Blegny | €1.6m | €140,804 | -58.0% | 2.6 |
| UDental Asse | €1.4m | €375,172 | 12.2% | 5.2 |
| Biosynex Pharma Benelux Saint-Josse-ten-Noode | €2.9m | €259,103 | 57.8% | 7.2 |
| ENDOCEUTICS Brussels | €3.5m | €415,353 | 6.8% | - |
These companies have the same main activity as XTRAPHARMA: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €1.4m and €3.5m, founded between 2018 and 2022.
Official details
Source: KBO- Status
- Active since 28-07-2020Normal situation
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460and 1 other
- Establishment unit
- 2.362.529.8221130 Brussels, since 15-10-2020
- Financial year end
- 31 December
- Peppol
- Reachable since 02-06-2025
Annual accounts 2025
- ≈ €1.2mestimated
- €2.2m▼ 1.3%
- Filing
- Filed on 29-07-2026, 2 days before the end of the filing period
Insights on XTRAPHARMA
XTRAPHARMA files the abbreviated format. That format states no turnover. The gross margin fell from €290,436 in 2021 to €228,023 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about XTRAPHARMA
- What is the company number of XTRAPHARMA?
- The company number of XTRAPHARMA is 0751.561.839. The VAT number is the same number with BE in front: BE 0751.561.839.
- Where is XTRAPHARMA based?
- The registered office is at Parochiestraat 22, 1130 Brussels.Company details
- What does XTRAPHARMA do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of XTRAPHARMA?
- XTRAPHARMA is a private limited company (BV).
- When was XTRAPHARMA founded?
- XTRAPHARMA was founded on 28-07-2020.
- Is XTRAPHARMA still active?
- Yes, XTRAPHARMA is an active enterprise in the KBO register.
- What is the turnover of XTRAPHARMA?
- The turnover in financial year 2025 is ≈ €1.2m. This figure is estimated from the gross margin of €228,023 and 102 comparable companies (NACE 46). It probably lies between €550,000 and €2.1m. In financial year 2023 turnover was €8.6m.Financials
- Is XTRAPHARMA profitable?
- In financial year 2025, XTRAPHARMA made a profit of €142,634.
- Where can I find the annual accounts of XTRAPHARMA?
- XTRAPHARMA filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of XTRAPHARMA due?
- XTRAPHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.